Bureaucratic barriers to cystic fibrosis treatment in USA

The Cystic Fibrosis Engagement Network, a project of the Alliance for Patient Access, today released a new white paper, “ Making Treatment Accessible for Cystic Fibrosis Patients.”

The white paper details what is standing in the way of patient access to new treatments approved to target some of the genetic mutations that cause cystic fibrosis – and how addressing bureaucratic barriers could help the 30,000 Americans living with this rare disease. For the patients with specific mutations, these treatments can significantly improve lung function and quality of life.

The white paper pinpoints two key barriers to treatment: